Quotient Sciences, a CDMO that specializes in “niche and smaller volume” drugs, has extended a deal with Ipsen to manufacture Sohonos (palovarotene) capsules. Sohonos is currently the only medication approved by the FDA to treat the ultra-rare disease fibrodysplasia ossificans progressiva.
CDMO Quotient extends Ipsen supply pact for rare disease drug Sohonos
Latest from Blog
NEWS CENTER Maine
Through in-depth storytelling, through direct contact on digital on social platforms, through long-standing community service programs like Coats & Toys for Kids, Project Heat and Buddy to Buddy, NEWS CENTER Maine is
Four Rules for Fueling that Every Senior Cyclist Should Follow, According to a Dietitian and Cycling Coach
Thankfully, the era of “eating is cheating” is over. Post Views: 4
It’s Nutrition and Hydration Week — Here’s some tips on how to eat healthy on a budget
This week is Nutrition and Hydration Week, an annual week aimed at highlighting and promoting improvements in nutrition and hydration. Local organizations like Second Harvest Food Bank said eating wel… Post Views:
STAT+: Automatic enrollment in Medicare Advantage plans under consideration, top Trump health official says
President Trump’s Medicare director said Thursday his team is considering a policy that would automatically enroll Medicare beneficiaries into Medicare Advantage plans, a controversial idea that was touted in the conservative Project